Trevi Therapeutics (TRVI) Total Non-Current Liabilities (2018 - 2022)
Trevi Therapeutics (TRVI) posted quarterly Total Non-Current Liabilities of $15.6 million for Q4 2022, down 26.93% year-over-year from $21.3 million in Q4 2021, and down 15.67% quarter-over-quarter from $18.4 million in Q3 2022.
Trevi Therapeutics (TRVI) Total Non-Current Liabilities (2018 - 2022) Analysis & Trends
Trevi Therapeutics' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $15.6 million for Q4 2022.
- In Q4 2022, Total Non-Current Liabilities fell 26.93% year-over-year to $15.6 million; the TTM figure through Dec 2022 stood at $15.6 million (down 26.93% YoY), while the FY2022 annual figure was $15.6 million, down 26.93% from the prior year.
- Total Non-Current Liabilities for Q4 2022 stood at $15.6 million, down from $18.4 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $55.7 million in Q3 2020, with the low at $9.4 million in Q4 2018.
- The 4-year median for Total Non-Current Liabilities is $19.8 million (2022), against an average of $21.9 million.
- Peak annual rise in Total Non-Current Liabilities reached 8.31% in 2021, while the deepest fall reached 64.0% in 2021.
- Trevi Therapeutics' Total Non-Current Liabilities stood at $9.4 million in 2018, then surged by 108.41% to $19.7 million in 2020, then gained by 8.31% to $21.3 million in 2021, then decreased by 26.93% to $15.6 million in 2022.
- Business Quant data shows TRVI's Total Non-Current Liabilities at $15.6 million in Q4 2022, $18.4 million in Q3 2022, and $20.9 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 15.55 Mn |
| Sep 30, 2022 | 18.44 Mn |
| Jun 30, 2022 | 20.86 Mn |
| Mar 31, 2022 | 19.80 Mn |
| Dec 31, 2021 | 21.29 Mn |
| Sep 30, 2021 | 20.05 Mn |
| Jun 30, 2021 | 21.38 Mn |
| Mar 31, 2021 | 18.98 Mn |
| Dec 31, 2020 | 19.65 Mn |
| Sep 30, 2020 | 55.69 Mn |
| Dec 31, 2018 | 9.43 Mn |